Literature DB >> 2933917

The effects of dichloromethylene biphosphonate on osteoporotic femora of adult castrate male rats.

C S Wink, M S Onge, B Parker.   

Abstract

In a previous study we reported that castration of adult male rats resulted in femoral osteoporosis 4 months later. The present study tested the effects of dichloromethylene biphosphonate (Cl2MBP, formerly Cl2MDP), a bone resorption inhibitor, on the development of osteoporosis in femora of adult castrated male rats. One-year-old male Holtzman rats were assigned to three groups: sham-operated controls; castrated-no treatment; castrated + Cl2MBP injections 3 times/week. The animals were sacrificed 4 months later. Femora from untreated castrated rats were osteoporotic, confirming our earlier study. Femora from Cl2MBP-treated castrates did not differ from those of controls and were significantly denser and more robust than those of untreated castrated rats. The results indicated that Cl2MBP treatment started immediately after castration prevented the development of femoral osteoporosis in adult castrated male rats.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933917     DOI: 10.1159/000146105

Source DB:  PubMed          Journal:  Acta Anat (Basel)        ISSN: 0001-5180


  5 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 3.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 4.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

Review 5.  Drugs in development: bisphosphonates and metalloproteinase inhibitors.

Authors:  Jon B Catterall; Tim E Cawston
Journal:  Arthritis Res Ther       Date:  2002-11-08       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.